Two- versus five-fraction stereotactic ablative radiotherapy for intermediate-risk prostate cancer
PHASE II RANDOMIZED TRIAL OF 2- VS 5-FRACTION PROSTATE STEREOTACTIC ABLATIVE RADIOTHERAPY
This trial tests whether giving prostate SABR in 2 treatments instead of 5 is as safe and effective for men with intermediate-risk prostate cancer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | British Columbia Cancer Agency Academic / other |
| Drugs / interventions | radiation, chemotherapy, methotrexate |
| Locations | 1 site (Victoria, British Columbia) |
| Trial ID | NCT06835725 on ClinicalTrials.gov |
What this trial studies
This Phase II randomized trial compares late toxicity, quality of life, and biochemical disease control between prostate SABR delivered in 2 fractions versus the standard 5 fractions for men with intermediate-risk prostate cancer. Participants are randomized to receive image-guided stereotactic body radiation therapy with follow-up visits to record side effects, patient-reported outcomes, and PSA-based control. A secondary, offline analysis will explore the feasibility of adding an AI-driven dose guidance and adaptive positioning algorithm to the image-guidance workflow. The trial allows short-course androgen deprivation therapy for unfavorable intermediate-risk patients when clinically indicated.
Who should consider this trial
Good fit: Men aged 18 or older with histologically confirmed NCCN low- or intermediate-risk prostate adenocarcinoma, ECOG 0–2, life expectancy >5 years, and fit for prostate SABR are the intended participants.
Not a fit: Men with high-risk or metastatic prostate cancer, prior incompatible pelvic radiotherapy, or other conditions that preclude safe delivery of SABR are unlikely to benefit from this trial.
Why it matters
Potential benefit: If successful, the 2-fraction approach could shorten treatment from multiple visits to just two, improving convenience while potentially reducing some side effects and maintaining cancer control.
How similar studies have performed: Five-fraction prostate SABR has been shown in randomized trials to be non-inferior to conventional radiotherapy, while two-fraction regimens have shown encouraging results mainly in small single-arm studies but lack randomized confirmation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Age 18 or older. * Able to provide informed consent. * ECOG performance status 0 - 2. * Fit for all protocol treatment and follow-up. * Life Expectancy \> 5 years. * Histologically confirmed adenocarcinoma of the prostate, NCCN low or intermediate risk, with biopsy performed within the last 18 months: Low risk = cT1-T2a,Gleason ≤ 6, and PSA \< 10ng/mL. Intermediate risk = at least one of: cT2b/T2c, PSA 10-20ng/mL, or Gleason 7, but not high risk. * 6 months of Androgen Deprivation Therapy (ADT) is permitted for those with NCCN unfavorable intermediate risk disease (aka high-tier intermediate risk disease), defined as intermediate risk disease with one or more of: two or three intermediate risk features, Gleason 4+3, or ≥50% biopsy cores positive. * For those with NCCN unfavorable intermediate risk disease, it is permitted for ADT to have been initiated prior to study enrollment provided it is possible for radiotherapy to be completed before completion of 6 months of ADT. * Prostate volume \<100cc based on imaging or digital rectal examination. * PSA within 90 days prior to registration. If ADT is started before registration, then the PSA must have been done no more than 90 day prior to the date of the first ADT injection. * CT abdomen and pelvis within the 6 months prior to registration (may be omitted for NCCN low risk participants). If particpant started on ADT prior to registration, CT should be done before first ADT injection. * Bone scan within the 6 months prior to of registration (may be omitted for NCCN low risk participants). If particpant started on ADT prior to registration, bone scan should be done before first ADT injection. * Must be appropriate for and willing to undergo implantation of prostate fiducial markers and Space OAR Hydrogel. Exclusion Criteria: Clinical stage cT3 or greater. Gleason score 8 or greater. PSA \> 20ng/mL or greater. NCCN high or very high risk. Pelvic nodal metastases. Distant metastases. Previous malignancy within the last 5 years except basal or squamous cell carcinomas of the skin. Previous pelvic radiotherapy. Any prior active local treatment for prostate cancer. Participants previously on active surveillance are eligible if they continue to meet all other eligibility criteria. Unilateral or Bilateral hip prostheses. Medical conditions likely to make radiotherapy inadvisable (e.g., inflammatory bowel disease). Medical condition that would make implantation of fiducial markers or hydrogel rectal spacer unsafe, in the opinion of the treating physician (e.g., pelvic or prostate abscess). Medical condition or implant that prohibits MRI (e.g. pacemaker) Trans-urethral resection of the prostate (TURP), GreenLight Laser or Holmium Laser Prostate procedure within 6 months of radiotherapy.
Where this trial is running
Victoria, British Columbia
- BC Cancer Radiation Oncology — Victoria, British Columbia, Canada (Recruiting)
Study contacts
- Principal investigator: Abraham Alexander — BC Cancer
- Study coordinator: Cathy Tran
- Email: cathy.tran@bccancer.bc.ca
- Phone: 250 519 5500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.